… multicenter study, IBD patients receiving anti-TNF therapy … Ustekinumab’s long-term
safety was evaluated for 5 years in … Patients with positive hepatitis B surface antigen or virus …

… example, a retrospective epidemiologic study of patients treated in … ) ustekinumab has not
been assessed in a clinical trial in … In the multicenter study, 15 patients with GPP received five …

… , pyelonephritis, tuberculosis, or hepatitis B reactivation, as well as … A retrospective multicenter
study assessed the survival of … of 14 HS patients with an ustekinumab dosage regimen for …

… and are used in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis.
Secukinumab and ixekizumab are also approved for psoriatic arthritis and ankylosing spondylitis. …

… anti-TNF antibodies and ustekinumab for psoriatic arthritis, the … Safety concerns common in
biologics include hepatitis B … , and retrospectively matched controls [76]. They demonstrated …

… option for patients with IH in terms of safety. … (ustekinumab), and IL-23 inhibitors (guselkumab,
risankizumab, and tildrakizumab) (Table 3). In a retrospective German multicenter study …

… in patients exposed to corticosteroids and/or anti–tumor … for hepatitis B virus is regularly
expanded to hepatitis C virus testing… in the case of ustekinumab because there is no safety signal …

… showed superiority compared to anti-tumor necrosis factor (TNF)-… significant diseases, such
as hepatitis B, hepatitis C, and HIV, … A retrospective multicenter 28-week real-life study on 59 …

… uncontrolled retrospective case series and cohort studies in … In both trials, combining the
anti–tumor necrosis factor (TNF) … vedolizumab or ustekinumab, induces clinical response and …

… a key safety … clinically relevant topics were drafted. In an initial teleconference in October
2019, all participants discussed the PICO and non-PICO questions and agreed on the final set …